Encarnacion Sastre nackt sorted by
relevance

Admin06.09.2021

Encarnación Sastre

16 Hospital Universitario de Donostia, Medical Oncology Department, San Sebastian, Spain.
6103
Admin05.08.2021

Encarnación Sastre

Published by BMJ on behalf of the European Society for Medical Oncology.
2400
Admin21.07.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
6800
Admin25.07.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

18 University Hospital and Health Research Institute IDIS , CIBERONC, Santiago de Compostela University School of Medicine, Medical Oncology Department, Santiago de Compostela, Spain.
3802
Admin28.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

11 Hospital Universitario Virgen de las Nieves, Medical Oncology Department, Granada, Spain.
9202
Admin22.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, Ghezzi S, Bonazzina E, Bencardino K, Cerea G, Siena S, Sartore-Bianchi A.
9706
Admin24.07.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

SGC, ASS, PG-A, FR, GAQ-A, EGF, MSF and BG declare no potential conflicts of interest.
64010
Admin30.07.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Falcone A, Ricci S, Brunetti I, et al.
39010
Admin22.06.2021

Encarnación Sastre

The vertical dashed line indicates a HR of 1.
9403
Admin31.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan FOLFOXIRI compared with infusional fluorouracil, leucovorin, and irinotecan FOLFIRI as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
8606
Admin05.08.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

Masi G, Vasile E, Loupakis F, et al.
1601
Admin10.06.2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ

15 Hospital General Universitario de Valencia, Medical Oncology Department, Valencia, Spain.
4309